{"prompt": "['Novartis', 'Confidential', 'Page 65', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'The occurrence of relevant protocol deviations will be determined. After these actions have', 'been completed and the database has been declared to be complete and accurate, it will be', 'locked and the treatment codes will be unblinded and made available for data analysis. Any', 'changes to the database after that time can only be made after written agreement by Novartis', 'Development management.', '8.4', 'Data Monitoring Committee', 'An independent, external data monitoring committee (DMC) will be set up to review safety', 'data (including specific safety summaries for adolescent participants) from this trial and other', 'Phase 3 trials in the QAW039 asthma development program. The DMC will consist of a', 'group of experts independent of the sponsor; analyses for the DMC will be prepared by', 'individuals independent of the sponsor and sponsor personnel will remain fully blinded to', 'results until the final clinical database lock as described in Section 5.4. Based on the safety', 'implications of the data, the DMC may recommend modification or termination of the study.', 'No statistical adjustment will be made to the final analysis. Full details on procedures, the', 'DMC and futility criteria will be specified in a DMC charter.', '8.5', 'Adjudication Committee', 'Not required.', '9', 'Data analysis', 'The analysis will be conducted on all subject data at the time the trial ends. Any data analysis', 'carried out independently by the investigator should be submitted to Novartis before', 'publication or presentation.', 'The primary efficacy analysis of this pivotal trial will be based on the data of this trial alone.', 'In addition, efficacy data will also be pooled with the other identical Phase 3 trial and the', 'pooled data will be used to fully characterize efficacy in the asthma patient population studied', 'in these trials.', '9.1', 'Analysis sets', 'The screened set (SCR) will include all patients who provided informed consent.', 'The full analysis set (FAS) will include all randomized patients who received at least one dose', 'of study drug. It was considered reasonable to limit the FAS to patients who took trial', 'medication, because the decision on whether or not study drug is started will not be influenced', 'by the treatment group assignment due to the effective treatment blinding procedures', 'described in Section 5.4. Following the intent-to-treat principle, patients will be analyzed', 'according to the treatment they were assigned to at randomization.', 'The per-protocol set (PPS) will include all patients in the FAS without any major protocol', 'deviations such as violation of major entry criteria or low compliance. Patients may also be', 'considered censored for the PPS analysis at the time of major post-baseline protocol', 'deviations. Major protocol deviations will be defined in the study specification document']['Novartis', 'Confidential', 'Page 66', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2316', 'prior to database lock and the un-blinding of the study. Patients will be analyzed according to', 'the treatment they received.', 'The safety set (SAF) will include all patients who received at least one dose of double-blind', 'study drug. Patients will be analyzed according to the treatment they received.', 'The analysis of the primary objective will be performed on the FAS. The PPS will be used for', 'the supportive analysis of the primary and the secondary variables. The FAS will be used for', 'the analysis of all other efficacy variables. The SAF will be used in the analysis of all safety', 'variables.', '9.2', 'Patient demographics and other baseline characteristics', 'Patient demographics and baseline characteristics measured before randomization including', 'age (calculated from date of birth to date of Visit 1), sex, race, ethnicity, height, weight, body', 'mass index (BMI), relevant medical history, including smoking history, asthma duration, use', 'of long-acting beta-agonists, ICS dose ranges (medium, high) pre- and post- bronchodilator', 'FEV1, percent predicted FEV1,', 'ACQ score, AQLQ+12 score,', 'number of exacerbations in the previous year, and daytime asthma symptom scores will be', 'summarized by treatment group for the FAS. Categorizations of age will include at least the', 'categories of <18, 18 to <65, 65-74, 75-84 and >85 years of age.', '9.3', 'Treatments', 'The duration of exposure, the number of patients randomized who completed the foreseen', 'course of study drug and the number of patients who discontinued from the study drug will be', 'summarized.', 'Medications started and stopped prior to study drug, taken concomitantly, and started', 'following last study drug dose (if applicable) will be summarized by treatment group in', 'separate tables in the SAF. Concomitant therapies will be recorded, listed and summarized', 'separately for asthma related medications / non-drug therapies and other medications.', 'Concomitant asthma related medications will be summarized by pre-defined category.', 'Concomitant medications not related to asthma will be summarized by anatomical therapeutic', 'chemical (ATC) class and preferred term. More than one ATC class per medication is', 'possible and the medication will be reported under all applicable classes.', 'SABA usage (number of puffs) during the placebo run-in period will be summarized.', 'Usage of asthma medication (e.g., LABA, ICS) at baseline will be summarized (if applicable).', 'Patients taking prohibited concomitant medications will be noted in the summary of protocol', 'deviations.', 'Compliance with study drug over the entire study will be summarized as the percentage of', 'days with study drug intake during the period from first intake to last intake.', '9.4', 'Analysis of the primary variable(s)', 'The primary analysis for this study will be conducted according the intention to treat (ITT)', 'principle.']\n\n###\n\n", "completion": "END"}